Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug
- Jury rules no infringement by Teva generics Suboxone, Subutex
- Orexo had claimed damage to sales of its biggest drug, Zubsolv
This article is for subscribers only.
A U.S. jury on Friday rejected a claim by Sweden’s Orexo AB that two generic opioid-addiction treatments created by Teva Pharmaceutical Industries Ltd. infringed a patent for Orexo’s biggest drug, Zubsolv.
A Teva unit had created copies of the drugs Suboxone and Subutex, which are made by a third company, Indivior Plc, which wasn’t party to the lawsuit. Orexo had argued that the Teva products used the same essential formula as that covered by the patent for Zubsolv. After a trial in Wilmington, Delaware, federal court jurors disagreed.